1. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States Part III, Liver, biliary tract, and pancreas. Gastroenterology 2009, 136(4), 1134–1144
2. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 2002, 37(6), 806–813
3. Aljiffry M, Abdulelah A, Walsh M, Peltekian K, Alwayn I, Molinari M. Evidence-based approach to cholangiocarcinoma, a systematic review of the current literature. J Am Coll Surg 2009, 208(1), 134–147
4. DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, et al, Cholangiocarcinoma, thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007, 245(5), 755–762
5. Gores GJ. Cholangiocarcinoma, current concepts and insights. Hepatology 2003, 37(5), 961–969
6. Patel T. Cholangiocarcinoma--controversies and challenges. Nat Rev Gastroenterol Hepatol 2011, 8(4), 189–200
7. Tadashi T, Kiyoko M, Noboru T, Yasuo S, Yasuni N. Alpha-smooth muscle actin-positive stromal cells in cholangiocarcinomas, hepatocellular carcinomas and metastatic liver carcinomas. J Hepatol 1996, 24(6), 706–712
8. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006, 6(5), 392– 401
9. Okabe H, Beppu T, Hayashi H, Horino K, Masuda T, Komori H et al. Hepatic stellate cells may relate to progression of intrahepatic cholangiocarcinoma. Ann Surg Oncol 2009, 16(9), 2555–2564
10. Chuaysri C, Thuwajit P, Paupairoj A, Chau-In S, Suthiphongchai T, Thuwajit C. Alpha-smooth muscle actin-positive fibroblasts promote biliary cell proliferation and correlate with poor survival in cholangiocarcinoma. Oncol Rep 2009, 21(4), 957–969
11. Sirica AE. The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 2011, 9(1), 44–54
12. Thongchot S, Ferraresi A, Vidoni C, Loilome W, Yongvanit P, Namwat N et al. Resveratrol interrupts the pro-invasive communication between cancer associated fibroblasts and cholangiocarcinoma cells. Cancer Lett 2018, 430, 160–171
13. Ishii N, Araki K, Yokobori T, Hagiwara K, Gantumur D, Yamanaka T et al. Conophylline suppresses pancreatic cancer desmoplasia and cancer-promoting cytokines produced by cancer-associated fibroblasts. Cancer Sci 2019, 110(1), 334–344
14. Wang T, Notta F, Navab R, Joseph J, Ibrahimov E, Xu J et al. Senescent Carcinoma-Associated Fibroblasts Upregulate IL8 to Enhance Prometastatic Phenotypes. Mol Cancer Res 2017, 15(1), 3–14
15. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U et al. BIBF 1120, triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008, 68(12), 4774–4782
16. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011, 365(12), 1079–1087
17. Richeldi L, Du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014, 370(22), 2071–2082
18. Wollin L, Maillet I, Quesniaux V, Holweg A, Ryffel B. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther 2014, 349(2), 209–220
19. Akcora BÖ, Storm G, Prakash J, Bansal R. Tyrosine kinase inhibitor BIBF1120 ameliorates inflammation, angiogenesis and fibrosis in CCl4-induced liver fibrogenesis mouse model. Sci Rep 2017, 7, 44545
20. Gabasa M, Ikemori R, Hilberg F, Reguart N, Alcaraz J. Nintedanib selectively inhibits the activation and tumour-promoting effects of fibroblasts from lung adenocarcinoma patients. Br J Cancer 2017, 117(8), 1128–1138
21. Lau EY, Lo J, Cheng BY, Ma MK, Lee JM, Ng JK et al. Cancer-Associated Fibroblasts Regulate Tumor-Initiating Cell Plasticity in Hepatocellular Carcinoma through c-Met/FRA1/HEY1 Signaling. Cell Rep 2016, 15(6), 1175–1189
22. Mertens JC, Fingas CD, Christensen JD, Smoot RL, Bronk SF, Werneburg NW et al. Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma. Cancer Res 2013, 73(2), 897–907
23. Heits N, Heinze T, Bernsmeier A, Kerber J, Hauser C, Becker T et al. Influence of mTOR-inhibitors and mycophenolic acid on human cholangiocellular carcinoma and cancer associated fibroblasts. BMC Cancer 2016, 16, 322
24. Kubo N, Saito R, Hamano K, Nagasawa M, Aoki F, Takei I et al. Conophylline suppresses hepatic stellate cells and attenuates thioacetamide-induced liver fibrosis in rats. Liver Int 2014, 34(7), 1057–1067
25. Saito R, Yamada S, Yamamoto Y, Kodera T, Hara A, Tanaka Y et al. Conophylline suppresses pancreatic stellate cells and improves islet fibrosis in Goto-Kakizaki rats. Endocrinology 2012, 153(2), 621–630
26. Elenbaas B, Weinberg RA. Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp Cell Res 2001, 264(1), 169–184
27. Kuzet SE, Gaggioli C. Fibroblast activation in cancer, when seed fertilizes soil. Cell Tissue Res 2016, 365(3), 607–619
28. MacKenzie B, Korfei M, Henneke I, Sibinska Z, Tian X, Hezel S et al. Increased FGF1-FGFRc expression in idiopathic pulmonary fibrosis. Respir Res 2015, 16, 83
29. Cadamuro M, Nardo G, Indraccolo S, Dall'Olmo L, Sambado L, Moserle L et al. Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma. Hepatology 2013, 58(3), 1042–1053
30. Van Cutsem E, Yoshino T, Lenz HJ, Lonardi S, Falcone A, Limón ML et al. Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1), a phase III, international, randomized, placebo-controlled study. Ann Oncol 2018, 29(9), 1955–1963
31. Popat S, Mellemgaard A, Fahrbach K, Martin A, Rizzo M, Kaiser R et al. Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer, a network meta-analysis. Future Oncol 2015, 11(3), 409–420
32. Isomoto H, Kobayashi S, Werneburg NW, Bronk SF, Guicciardi ME, Frank DA et al. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology 2005, 42(6), 1329–1338
33. Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signalling in cancer, new and unexpected biological functions. Nat Rev Cancer 2014, 14(11), 736– 746
34. Zheng T, Hong X, Wang J, Pei T, Liang Y, Yin D et al. Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma. Hepatology 2014, 59(3), 935–946
35. Frampton G, Invernizzi P, Bernuzzi F, Pae HY, Quinn M, Horvat D et al. Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism. Gut 2012, 61(2), 268–277
36. Lai Y, Liu XH, Zeng Y, Zhang Y, Shen Y, Liu Y. Interleukin-8 induces the endothelial cell migration through the Rac 1/RhoA-p38MAPK pathway. Eur Rev Med Pharmacol Sci 2012, 16(5), 630–638
37. Palena C, Hamilton DH, RI Fernando. Influence of IL-8 on the epithelial-mesenchymal transition and the tumor microenvironment. Future Oncol 2012, 8(6), 713–722
38. Lu X, Mu E, Wei Y, Riethdorf S, Yang Q, Yuan M et al. VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors. Cancer Cell 2011, 20(6), 701–714
39. Peng H, Zhang Q, Li J, Zhang N, Hua Y, Xu L et al. Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma. Oncotarget 2016, 7(13), 17220–17229
40. Chatterjee S, Heukamp LC, Siobal M, Schöttle J, Wieczorek C, Peifer M et al. Tumor VEGF, VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. J Clin Invest 2013, 123(4), 1732–1740
41. Sulpice L, Rayar M, Desille M, Turlin B, Fautrel A, Boucher E et al. Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma. Hepatology 2013, 58(6), 1992–2000
42. Zheng Y, Zhou C, Yu XX, Wu C, Jia HL, Gao XM et al. Osteopontin promotes metastasis of intrahepatic cholangiocarcinoma through recruiting MAPK1 and mediating Ser675 phosphorylation of beta-Catenin. Cell Death Dis 2018, 9(2), 179
43. Guo Y, Xu F, Lu T, Duan Z, Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 2012, 38(7), 904–910
44. Sun L, Wang Q, Chen B, Zhao Y, Shen B, Wang H et al. Gastric cancer mesenchymal stem cells derived IL-8 induces PD-L1 expression in gastric cancer cells via STAT3/mTOR-c-Myc signal axis. Cell Death Dis 2018, 9(9), 928
45. Zhao D, Pan C, Sun J, Gilbert C, Drews-Elger K, Azzam DJ et al. VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2. Oncogene 2015, 34(24), 3107–3119
46. Huyen NT, Prachayasittikul V, Chan-On W. Anoikis-resistant cholangiocarcinoma cells display aggressive characteristics and increase STAT3 activation. J Hepatobiliary Pancreat Sci 2016, 23(7), 397–405
47. Gong J, Muñoz AR, Pingali S, Payton‐Stewart F, Chan DE, Freeman JW et al. Downregulation of STAT3/NF-kappaB potentiates gemcitabine activity in pancreatic cancer cells. Mol Carcinog 2017, 56(2), 402–411
48. Wormann SM et al. Loss of P53 function activates JAK2-STAT3 signaling to promote pancreatic tumor growth, stroma modification, and gemcitabine resistance in mice and is associated with patient survival. Gastroenterology 2016, 151(1), 180– 193e12
論文の公開元へ
